← Back to Clinical Trials
Recruiting Phase 1 NCT06970301

A Study to Assess the Safety and Tolerability, and Pharmacokinetics of UCB0022 in Healthy Caucasian, Japanese, and Chinese Participants

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Healthy Study Participants
Sponsor UCB Biopharma SRL
Study Type INTERVENTIONAL
Phase Phase 1
Enrollment 32
Sex ALL
Min Age 18 Years
Max Age 55 Years
Start Date 2025-04-28
Completion 2026-05-29
Interventions
glovadalenPlacebo

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The primary purpose of this study is to assess the safety and tolerability of oral glovadalen (UCB0022) in healthy Caucasian, Japanese, and Chinese participants.

Eligibility Criteria

Inclusion Criteria: * Healthy male and female participants must be 18 to 55 years of age inclusive at the time of signing the informed consent form (ICF). * Participants who are overtly healthy (in the opinion of the investigator) as determined by medical evaluation including medical history (any chronic and acute illness), physical examination, vital signs, 12-lead electrocardiogram (ECG), and laboratory tests during the Screening Period. Participants with test results that are outside the specified normal ranges and that are deemed not clinically significant will be allowed at the discretion of the investigator. If participants have a test result outside the specific range that is deemed clinically significant, repeat of the investigation may be allowed at the discretion of the investigator. * For Japanese participants: Participants are of Japanese descent as evidenced by appearance and verbal confirmation of familial heritage (participant have all 4 Japanese grandparents born in Jap

Related Trials

}
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology